Atoltivimab
Product Specifications
UNSPSC Description
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].
Target Antigen
Filovirus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/atoltivimab.html
Purity
98.66
Solubility
10 mM in DMSO
Smiles
[Atoltivimab]
References & Citations
[1]Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc). 2021 Aug;57(8):483-490.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99343/Atoltivimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99343/Atoltivimab-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2135632-29-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1018231-01 0.02 mg (E-Coli)
Recombinant Schizosaccharomyces pombe Serine/threonine-protein kinase ppk27 (ppk27)
Ask
View Details 
MBS1018231-02 0.02 mg (Yeast)
Recombinant Schizosaccharomyces pombe Serine/threonine-protein kinase ppk27 (ppk27)
Ask
View Details MBS1018231-03 0.1 mg (E-Coli)
Recombinant Schizosaccharomyces pombe Serine/threonine-protein kinase ppk27 (ppk27)
Ask
View Details